Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Breast Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

  • Blocking DNA Repair in Advanced BRCA-Mutated Cancer
    (Posted: 01/31/2014) - In this trial, patients with relapsed or refractory advanced cancer and confirmed BRCA mutations who have not previously been treated with a PARP inhibitor will be given BMN 673 by mouth once a day in 28-day cycles.
  • Potentially Less Toxic Adjuvant Chemotherapy for Women with Breast Cancer
    (Posted: 04/11/2013) - In this phase III trial, women with resected HER2-negative breast cancer that has either spread to nearby lymph nodes or has characteristics associated with a high risk of recurrence will be randomly assigned to receive one of four anthracycline-based chemotherapy regimens or six courses of docetaxel and cyclophosphamide.
  • Refining Post-Surgical Therapy for Women with Lymph Node-Positive Breast Cancer
    (Posted: 02/05/2013) - In this phase III trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomly assigned either to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy without chemotherapy.
  • Comparing Relaxation Programs for Breast Cancer Patients Receiving Radiotherapy
    (Posted: 10/16/2012) - In this study, women with breast cancer who have had surgery and are scheduled to undergo radiation therapy will be randomly assigned to one of two different stretching and relaxation programs or to a control group that will receive usual care.
  • Comparing Radiation Therapy Regimens for Early-Stage Breast Cancer
    (Posted: 10/02/2012) - In this phase III clinical trial, women with early-stage breast cancer will be randomly assigned to undergo a standard 5-week course of whole-breast irradiation (WBI) followed by a sequential boost course or 3 weeks of hypofractionated WBI with a concurrent boost.
1 2 3 4 5 6  Next >